Gynecologic Cancers
Pain Management

Restrictive Opioid Protocol After Gynecologic Surgery May Reduce Opioid Scripts but Not Pain Control

THE NUMBER of opioids prescribed after surgery for gynecologic cancer decreased significantly after implementation of an ultra-restrictive opioid prescription...

 

Lung Cancer

Early Evidence of Neoadjuvant PD-1 Blockade in Non–Small Cell Lung Cancer

A novel approach using two doses of nivolumab prior to surgery achieved major pathologic responses in 45% of patients with resectable stages I to IIIA...

 

Skin Cancer

Durable Complete Responses After Discontinuation of Pembrolizumab in Metastatic Melanoma

As reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, and colleagues, a high proportion of patients...

 


Advertisement
Kidney Cancer

CheckMate 214: Nivolumab Plus Ipilimumab Improves Survival vs Sunitinib in Advanced Renal Cell Cancer

As reported in The New England Journal of Medicine by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase III CheckMate 214...

 

Solid Tumors
Skin Cancer

Dabrafenib Plus Trametinib for Thyroid Cancer, Melanoma With BRAF Mutations

On May 4, 2018, dabrafenib and trametinib in combination was granted approval for treatment of patients with locally advanced or metastatic...

 


More Top Stories

Nancy Davidson: Serendipity and Purpose (with Allen S. Lichter, MD)

Gynecologic Cancers

Clinical Findings Predict Early Treatment Discontinuation in Patients Receiving Immunotherapy for Ovarian Cancer

PRETREATMENT CLINICAL findings may predict early treatment discontinuation in patients with ovarian cancer receiving checkpoint blockade immunotherapy agents. Data presented by MD candidate Julia L. Boland at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer revealed that...

Advertisement

EHA 2018: Tisagenlecleucel Demonstrates More Than 1-Year Durability of Response in Adults With Relapsed or Refractory DLBCL

Fourteen-month results from the JULIET clinical trial showed ongoing durable responses are achievable with tisagenlecleucel (Kymriah) when administered to adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This updated analysis was presented by Borchmann et al at ...

Bruce E. Johnson, MD, and Monica M. Bertagnolli, MD, on The ASCO Presidency: Passing the Torch

‘Pearls of Wisdom’ for Leadership and Success in Academic Medicine Gathered Over a 35-Year Career

Dr. Hayes, ASCO President 2016–2017, is Professor of Internal Medicine; Stuart B. Padnos Professor in Breast Cancer; and Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, Ann Arbor. AS I COMPLETE my 3-year term as ASCO President, I am...

St. Baldrick’s Foundation and SU2C Support Pediatric Cancer Research

The collaboration between Stand Up To Cancer (SU2C) and St. Baldrick’s Foundation Pediatric Cancer, launched in 2013, continues to help develop new immunotherapy approaches to high-risk childhood cancers, with the most recent donation of $8 million from the St. Baldrick’s Foundation. In addition,...

KEYNOTE-224: Pembrolizumab in Advanced Hepatocellular Carcinoma Pretreated With Sorafenib

As reported in The Lancet Oncology by Zhu et al, the phase II KEYNOTE-224 study has shown activity of pembrolizumab in advanced hepatocellular carcinoma (HCC) pretreated with sorafenib. Study Details In the study, 104 eligible patients who were intolerant of or progressed on sorafenib were...

Breast Cancer

Sherry Shen, MD, on Breast Cancer and Obesity: Results of the SWOG S0927 Study

Head and Neck Cancer

Mobile and Sensor Technology May Lead to Reduced Symptoms of Head and Neck Cancer and Its Treatment

A RANDOMIZED clinical trial evaluating the use of mobile and sensor technology to remotely monitor symptoms in patients receiving radiation therapy for head and neck cancer found that use of this technology reduced the severity of symptoms related to cancer and its treatment compared with usual...

Advertisement

FDA Clears Expanded Indication of Scalp-Cooling System

Paxman’s advanced scalp-cooling system has now been cleared by the US Food and Drug Administration (FDA) for use during treatment of patients with solid tumors. The system is now indicated to reduce the likelihood of chemotherapy-induced alopecia in cancer patients with solid tumors such as...


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.